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Abstract
Cell-based therapy exploits modified human cells to treat diseases but its targeted application in 
specific tissues, particularly those lying deep in the body where direct injection is not possible, has 
been problematic. Here we use a magnetic resonance imaging (MRI) system to direct 
macrophages carrying an oncolytic virus, Seprehvir, into primary and metastatic tumour sites in 
mice. To achieve this, we magnetically label macrophages with super-paramagnetic iron oxide 
nanoparticles (SPIOs) and apply pulsed magnetic-field gradients in the direction of the tumour 
sites. Magnetic resonance targeting guides macrophages from the bloodstream into tumors, 
resulting in increased tumour macrophage infiltration and reduction in tumor burden and 
metastasis. Our study indicates that clinical MRI scanners can not only track the location of 
magnetically labelled cells but also have the potential to steer them into one or more target tissues.
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Introduction
Advances in our understanding of the molecular mechanisms underpinning major diseases 
have led to the development of a wide array of cell-based therapies to deliver a therapeutic 
agent like a protein or virus, or a modified, repopulating stem cell1. When the disease is not 
confined to one site in the body, or is in a tissue inaccessible by direct injection of cells, 
such cell-based therapies have to be administered systemically.
Previous studies have shown that magnetic particles or cells loaded with SPIOs can be 
injected systemically and attracted to a target tissue in mice by the application of a local 
external magnet2-6. Indeed, we have previously showed that SPIO-loaded human 
macrophages could be attracted from the circulation into tumors in mice using such an 
approach7. However, this approach can only be applied to superficial target tissues. While 
localised magnetic field gradients could be achieved in deeper tissues using implanted 
ferromagnetic stents8, this necessitates invasive surgery.
An exciting, alternative approach is magnetic resonance targeting (MRT) which uses the 
magnetic field gradient coils inherent to all magnetic resonance imaging (MRI) systems, to 
steer ferromagnetic particles (or cells containing them) to a target site4. We have previously 
shown that MRI could be used to steer iron-labeled human PBMCs in a vascular model7, 
and early studies in pigs demonstrated this concept by steering a 1.5mm ball bearing a 
distance of 5cm inside the right carotid artery of the animal using the gradient coil currents 
of a standard 1.5 T MRI system9,10.
Bone marrow-derived cells (BMDCs) are increasingly being used in cell-based therapies for 
such diseases as infarcted myocardium11, spinal cord injury12, cerebral ischemia13, 
degenerative diseases like Parkinson’s Disease14, Alzheimer’s Disease15 and cancer16-18. In 
the latter disease, numerous clinical trials have administered bone marrow-derived cells 
systemically in an attempt to treat malignant tumors, including T-cells19,20, dendritic cells21, 
macrophages22,23 and stem cells24. However, only a small proportion of these cells 
subsequently locate to the tumor site, with many found subsequently in other tissues. This 
lack of targeting not only reduces the therapeutic efficacy but also increases the risk of side 
effects.
When macrophages were found to accumulate in large numbers in avascular hypoxic/
necrotic areas of such tissues in mice and humans17,25,26 we suggested that these cells could 
be used to deliver therapeutic agents like oncolytic viruses (OV) to these poorly 
vascularized, and therefore relatively inaccessible, areas of tumors17. In the present report, 
we show that MR targeting can be used to increase the number of OV-loaded macrophages 
in primary and metastatic tumors in mice. Importantly, MR targeting markedly increased the 
anti-tumor effects of this macrophage virotherapy. Our results suggests that it is possible to 
use a standard MRI scanner to non-invasively steer cells to both primary and secondary 
tumors, and so, in theory, this approach could be used to steer any cell-based therapy to its 
target site(s) within the body.
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Results
MR targeting of magnetic cells into 3D tumour spheroids
Before applying MR targeting techniques in vivo we first established that a pre-clinical 7T 
MRI system fitted with a 600mT/m gradient coil (limited to ~300mT per m for this study) 
set could generate substantial actuation forces on magnetic macrophages in vitro by steering 
them across an endothelial layer into 3D human multi-cellular tumor spheroids (MTS). To 
do this, we designed a trans-endothelial migration (TEM) flow chamber in which human 
macrophages circulated across the surface of a perforated membrane coated with a layer of 
human vascular endothelial cells, thereby mimicking flow in tumor venules. MTS were 
cultured in a non-adherent chamber below the membrane (Fig. 1a). Human macrophages 
transfected to express a GFP reporter adenovirus (Ad-CMV-GFP) were loaded with SPIOs 
(1.18ug per ml ± 0.3)7 and then steered across the membrane into MTS when the chamber 
was placed in the iso-centre of a pre-clinical MRI system.
MR targeting (MRT) experiments used a pulsed magnetic field gradient (2 ms on, 7 ms off, 
50% strength ~300mT per m4) for 1 hour in the direction of the spheroids (Fig. 1a) with an 
effective additional magnetic field offset, Boff ~ +1.5mT around the MTS site. In control 
conditions samples were exposed to the magnetic field of the scanner but gradients were not 
pulsed. Following MRT, we found a T2*-weighted signal loss indicating higher 
concentration of iron in comparison to the control samples for MRT samples (n=6) (Fig 1.c, 
upper panel). GFP-expressing macrophages were also clearly visible within MTS (Fig 1.c, 
2nd panel) and flow analysis further confirmed macrophage uptake with significantly more 
viable infiltrating CD14+/PI− expressing macrophages with MR targeting (29.7%±2.6) than 
without (2.9%±1.8) (Fig. 1 c, lower panel).
MRT improves tumour uptake of magnetic cells in vivo
We then investigated whether such an MRI gradient system could be used to steer magnetic 
macrophages to tumors in vivo (Fig. 2). Three million SPIO-loaded macrophages were 
administered intravenously to mice bearing orthotopic primary and metastatic (lung) 
prostate tumors. A pulsed magnetic field gradient4 was applied for 1 hour, in the direction of 
the prostate (Fig. 2a), with an effective magnetic field offset, Boff ~ +7mT on top of the 
static magnetic field of the scanner (B0 = 7T). The control group were exposed to the static 
magnetic field of the scanner in the absence of the steering gradients (no MR targeting).
MR targeting significantly (unpaired student t-test p=0.0001) increased uptake of SPIO-
loaded macrophages in primary prostate tumors (42.2%±2.5) compared to the control group 
who did not undergo MR targeting (7.17%±0.8) (Fig. 2b). Moreover, we observed these 
SPIO+ human macrophages were distributed throughout tumors with very few signs of cell 
clumping in the tumor vasculature following MR targeting as seen by labeling sequential 
sections of tumors using an antibody against human CD68 (a pan macrophage marker) and a 
histological stain for iron (Prussian Blue or ‘PB’) (Fig. 2c). This was also confirmed by 
immunofluorescence staining where tumor cells are labelled with the anti-GFP antibody 
(green) and tumor infiltrating human macrophages with anti-CD68 (red) (Supplementary 
Fig. 1a). MRI steering of macrophages did not adversely affect the tumor vasculature 
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(Supplementary Fig. 1b); we examined the morphology and integrity of every CD31+ blood 
vessel in each of the 5 tumors in these 2 groups and found no differences between them. We 
could not see signs of endothelial cell disruption, nor were there any signs of blood clotting 
(e.g. platelet aggregation) in, or on the abluminal side of blood vessels after MRI targeting. 
In the multi-echo RARE MR images of tumors little difference can be seen between the MR 
targeting and no MR targeting groups (Fig. 2d). This is most likely due to the blood pool 
iron content per voxel. However, a marked difference between SPIO injected and non-
injected subjects is evident in the T2-weighted long TE images, with loss in signal intensity 
within the tumor indicating the presence of high concentrations of iron (Fig. 2e). In an effort 
to assess the increased uptake of magnetic macrophages in vivo we used MR relaxometry to 
measure the MR transverse relaxation decay rate (R2) in tumors in both groups. R2 
measurements were 21.8s−1 for the MR targeting group and 18.8s−1 for the control group. 
Normal R2 decay rate of tumor tissue without the presence of any SPIOs is also included for 
comparison (10.5s−1). The increased R2 decay rate indicated increased iron uptake for the 
MR targeting group, suggesting it is possible to assess the uptake with MRI, as seen with the 
post mortem analysis (Supplementary Fig. 1c). The difference in targeted and non-targeted 
R2 values was used to estimate the optimal echo time for analysing signal differences with 
spin echo-based MRI sequences (TE of 60ms). Using this TE, MR targeting leads to a 10% 
decrease in signal over the time-matched controls.
Additional controls included tumor-bearing mice: (i) with unlabelled macrophages and MR 
targeting, and (ii) with unlabelled macrophages without MR targeting. For these control 
groups, we detected very few macrophages within tumors as confirmed by MRI imaging 
(Supplementary Fig. 1d) and flow cytometry of enzymatically dispersed tumors 
(Supplementary Fig. 1e). Of note, we detected virtually no human CD68+ macrophages in 
other tissues including the liver (<2% of all cells per tissue section), spleen (<1%) and 
kidneys (none detected) (Supplementary Fig. 2).
To further investigate if macrophage delivery to tumours by MRT disrupted the function or 
integrity of the tumour vasculature, vascular perfusion and permeability was determined 
using i.v. tomato lectin and Ricinus communis agglutinin I staining respectively27. We could 
not detect any differences in the number of perfused vessels or vascular leakage between the 
no MRT and +MRT groups (Fig. 2f). This was confirmed by estimating vascular 
permeability to gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) by dynamic 
contrast-enhanced (DCE) MRI (Fig. 3).
MR Targeting of magnetic cells to pulmonary metastasis
MR targeting has particular application when tumors are difficult or impossible to remove 
surgically, as in the lung, brain, liver or spinal cord and may enable delivery of cell-based 
therapies to primary or metastatic tumors in such locations. In a second in vivo experiment 
we used MR targeting to steer SPIO-labelled macrophages into the lungs of our mice 
bearing metastatic prostate tumors (Fig. 4). This was done immediately after i.v. 
administration of 3 million macrophages. Mice not exposed to MR targeting, but exposed to 
the magnetic field of the scanner for the same length of time, were used as controls.
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Flow cytometric analysis of enzymatically dispersed lungs showed the presence of 
significantly more human CD14+ macrophages following MR targeting than in the control 
group (17.7%±4 vs. 4.4%±2.6, respectively) (Fig. 4a). This was also confirmed by 
histological and immunofluorescence staining of lungs, where human CD68+ macrophages 
were detected in or close to the small metastatic deposits present within the lungs of mice 
following MR targeting (Fig. 4b and Supplementary Fig. 3a). These macrophages also 
stained positive for PB (iron) (Fig. 4b) and their iron content was also visible following 
H&E staining (Supplementary Fig. 3b). We inspected the morphology of CD31+ blood 
vessels in the lungs following their uptake of SPIO-labelled macrophages with or without 
MRT (Fig. 4c). Due to the short T2/T2* of lung tissue it was not possible to image the lung 
parenchyma with conventional 1H MRI techniques at high field for in vivo validation of 
increased uptake. Future technical developments may make this possible, for example the 
use of hyperpolarised gases in the airspaces could be used as an indirect MR signal detection 
method28. Nevertheless, in different organs or soft tissues, or on clinical systems, T2* 
imaging may have a place.
MR targeting of oncolytic macrophages reduces tumor growth
In a final experiment to assess the therapeutic benefits of MR targeting, SPIO-loaded 
macrophages armed with the OV, Seprehvir (HSV1716), were administered to tumor 
bearing mice. HSV1716 replication is supported by PC3 prostate cancer cells29 and here we 
show, for the first time, oncolysis in LNCaP cells in both hypoxic (0.5% O2) and normoxic 
(20%O2) conditions (Supplementary Fig. 4a). Seprehvir is readily taken up by macrophages 
and whilst uptake is significantly higher in normoxic culture conditions (Supplementary Fig. 
4b), viral replication is greater in hypoxia and macrophage cell death is equally effective in a 
hypoxic environment (Supplementary Fig. 4c,d). In our in vivo model, tumor-bearing mice 
received either a single intravenous injection of OV-carrying macrophages (MDM+OV), 
were placed in the static field of the scanner without MR targeting ‘MDM+OV(noMRT)’, or 
were exposed to the scanner with MR targeting (MDM+OV+MRT). For the purpose of 
comparison “free” OV was administered to a separate group of mice. Additional control 
groups of mice received either 100ul saline treatment (Control) or 3 million untreated 
macrophages (MDM) intravenously. OV (1×107 pfu)29 alone significantly delayed primary 
tumor growth for up to 7 days compared to mice receiving PBS or MDM only (Fig. 5a). 
This effect was significantly prolonged with macrophage-mediated delivery of Seprehvir (p 
< 0.006 at day 14 and p<0.007 day 21, a one-way ANOVA followed by post-hoc Bonferroni 
test was used for statistical analysis) and concurred with our previous studies where 
macrophages carrying OV were more effective over viral infusion alone17,18. Of note, no 
differences were observed in mice receiving MDM+OV but were not exposed to the MRI 
scanner and MDM+OV (no MRT) where the latter is exposed to the scanner but with no 
steering. However, MR targeting of our macrophage virotherapy was not only better at 
reducing the growth of the primary tumors from day 7 onwards, but also delayed primary 
tumor regrowth for the entire experiment (Fig. 5a). Bioluminescence of mice receiving 
macrophage OV therapy with or without MR targeting on the first day of treatment (day 0) 
and at the end of the experiment (day 21) showed this marked reduction of the primary 
tumor (Fig. 5a&b). This was confirmed visually on the MRI scans (Fig. 5c). Furthermore, 
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tumors undergoing MR targeting following macrophage-delivered OV were significantly 
more necrotic than those not receiving MR targeting (Fig. 5d).
In the lungs, few metastases were detected in mice injected with PBS or MDM alone since 
mice had to be culled at day 14 (due to the large size of their primary tumors). Therefore, it 
was not valid to compare metastases in these control groups with the other experimental 
groups. However, as shown in Fig. 5e the number of lung metastases was markedly reduced 
in mice that received MR targeted, OV-bearing macrophages than in those which received 
the cells but not MR targeting.
Discussion
In this study we show that an MRI scanner can be used to non-invasively steer cells to both 
primary and secondary tumors within the body leading to a significant improvement in 
therapeutic outcome. Moreover, relaxometry measurements suggest that standard MR 
imaging can then be used to monitor the efficacy of this therapy. Whilst this study has 
focused on cell delivery to tumors, the technology could be used to target any cells (e.g. 
mesenchymal stem cells, etc.) to a given tissue in the body including non-phagocytic cell 
types which could be ‘magnetised’ using SPIO-conjugated antibodies directed against 
proteins on their cell surface (Fig. 6).
The use of magnetic resonance targeting, which exploits the magnetic field gradients within 
magnetic resonance imaging systems to increase delivery of cells, is ideally suited to deep or 
superficial tissue7. The question of clinical translation is dependent on the ability to provide 
the same targeting force on a clinical MRI system. Clinical scanners, with high performance 
magnetic field gradient systems of 300mT m−1, are already in use and as such have the 
potential to produce similar forces30. Moreover, we were able to image the cell distributions 
following MRT, indicating the possibility for real-time image-guided targeting using an 
MRI system. These findings support the potential value of MRT with concomitant imaging 
for improved targeting of cells for therapy.
Materials and Methods
Isolation and culture of human macrophages
All patients donating blood gave informed consent to the Sheffield blood Transfusion 
Service and all procedures have been approved by the University of Sheffield Ethics 
Committee. Mononuclear cells were isolated from platelet-depleted buffy coats (Blood 
Transfusion Service, Sheffield, UK) using Ficoll-Paque Plus (Amersham Pharmacia, St. 
Albans, UK). In brief, fifty million monocytes were plated into T75 tissue culture flasks 
(NUNC, UK) and after 2 h non-adherent cells were removed. The remaining adherent cells 
were cultured over 7 days in IMDM Medium (Lonza, UK) supplemented with 2 mmol L−1 
L-glutamine, 100 U mL−1 penicillin, 100 μg mL−1 streptomycin, and 2% human Ab serum 
(Lonza).
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Endothelial cell cultures
Human Umbilical Vein Endothelial Cells (HUVEC) were obtained from Promocell, 
(Heidelberg, Germany) and used in the experiments up to passage 8. Cells (150,000) were 
seeded for 24h onto collagen-coated (0.1 mg/ml, human type IV) membranes containing a 5 
μM pore PET membrane (Neuroprobe).
Human multi-cellular tumor spheroids
Human prostate cancer cell line, LNCaP (ATCC CRL-1740), were seeded (5 × 103) in 100 
μl medium into each well of a 2% agarose (Sigma, Dorset, UK) coated 96-well tissue culture 
plate. After 7–10 days, each well contained a tumor spheroid with an average diameter of 
700-800 μm.
Infection of primary macrophages
Day 3 MDMs were infected with a replication deficient adenovirus (CMV-AdV5-GFP) at 
MOI 100. The E1A/B-deleted adenoviral vectors, CMV-AdV5-GFP (driven by a CMV 
promoter) was isolated from a single plaque, expanded in 293 human embryonic kidney 
(HEK) cells All the viruses were purified by double caesium gradient centrifugation, and 
titered by plaque assay on 293 cells with the titer expressed as plaque forming units (PFU)/
cell. The MOI used in this study were previously optimized in macrophages and are 
described in17.
Cellular uptake of magnetic nanoparticles by macrophages
MDMs (infected with AdCMV-GFP) were cultured overnight with 100 μg/ml SPIOs (25 
nm) (Sigma-Aldrich, Poole, UK). SPIO accumulation in cells was previously assessed by 
flow cytometry and confirmed by attraction of the cells towards a magnet placed at the side 
of the culture dish as observed by light microscopy (Leica Microsystems UK Ltd). Cell 
viability following SPIO uptake by macrophages was also measured by flow cytometry and 
compared to cells that were not incubated with SPIOs using the DNA dye propidium iodide 
(PI, Sigma). Comparisons made using an unpaired student t-test revealed no statistically 
significant difference between the two groups p=0.4 (Supplementary Fig. 1b) N=3.
In vitro trans-endothelial flow assay
The trans-endothelial migration (TEM) chamber was assembled as shown in (Fig. 1a). 
SPIO-loaded MDM (1.5 ×105 cells/ml in PBS + 2% FCS) were flowed over the HUVEC 
monolayer at typical venous flow rates (1.1885 ml/min) at a sheer stress of 1.4 Dynes/cm2, 
this is equivalent to blood flow through post-capillary venules. The TEM chamber was 
positioned directly in the iso-centre at ~5mm distal of a 7 Tesla magnet (Bruker 
BioSpecAVANCEII, 310mm bore, MRI system B/C 70/30). The flow in the chamber was in 
the −z direction (in and out of the magnet bore). We used pulsed gradients 2 ms on, 7 ms off 
as described by Reigler et.al4. To steer SPIOs into the chamber containing tumor spheroids 
we applied a pulsed −y gradient at 50% strength to avoid over-heating (~300mT/m) for 30 
minutes. Post MR targeting a 1H volume resonator (Bruker, 300MHz, 1kW max, outer 
diameter 118mm per inner diameter 72mm) allowed capture of MR images (FLASH and 
RARE).
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Spheroid infiltration by MDMs was then assessed using a fluorescent microscope to detect 
the GFP positive cells and flow cytometry using enzymatically-dispersed spheroids. To 
determine the iron content within SPIO-loaded macrophages, cell pellets were solubilized in 
70% nitric acid for 7–14 days prior to analysis. Iron concentrations were quantified against a 
calibration standard iron solution (Fischer Scientific) by Atomic Emission Spectroscopy 
using Varian Vista-M PX.
Flow cytometric analysis
Single cell suspensions were obtained by trypsinizing MDMs (including co-transduced 
MDMs). Cells were then incubated with for 30 min at 4°C with mouse anti-CD14, 1:100 in 
PBS containing 1% BSA (Sigma) to prevent non-specific antibody binding. Alternatively, 
spheroids were digested using 0.25% trypsin/EDTA to separate the tumor cells and 
infiltrated macrophages and cell death was analyzed by flow cytometry by adding propidium 
iodide (Sigma) to the cells immediately before running on the flow cytometer.
Orthotopic prostate xenograft model
All mouse procedures were conducted in accordance with the UK Home Office Regulations 
under the Animals (Scientific Procedures) Act 1986 and the awarded project licence number 
under which these protocols were performed is PPL:40/3424. In addition the University of 
Sheffield Animal Welfare & Ethical Review Body approved all the in vivo experiments used 
in this study. Male CD1 athymic mice (aged 7-8 weeks, stock number 000711) were used in 
these studies (Charles Rivers, UK). Animals were randomized before beginning the 
treatment schedule and were kept in ventilated cages with food and water provided ad 
libitum. Animal group sizes were calculated by power analysis. In general, a maximum of 5 
animals per group were used unless otherwise stated. One million LNCaP:LUC:GFP cells (a 
gift from Professor Magnus Essand, Uppsala Sweden) were mixed 1:1 in Matrigel and 
injected into the dorsolateral prostate. Tumor size was determined by administering luciferin 
(Molecular Probes) followed by bioluminescent IVIS imaging and measuring the daily 
weights of the mice. Tumor take was monitored by bioluminescence imaging using the IVIS 
Lumina II imaging system (Caliper Life Sciences). This detects live luciferase-labeled tumor 
cells, enabling real-time monitoring of tumor growth and spread in the mice. The mice were 
injected intraperitoneally (i.p.) with 90 mg/kg D-luciferin (Caliper Life Sciences) dissolved 
in sterile water and anaesthetized using 2.5% isoflurane (Abbott Scandinavia AB) in 100% 
oxygen at 3.5 L/min (for induction) in the anesthesia chamber of the imaging system. Mice 
were transferred to the dark box and isoflurane was lowered to 1.5%. Images were taken 
every 3 minutes as a sequence of 10 images for every group of mice, once a week. 
Automatic contour regions of interest were created, and the tumor sizes (or tumor radiance) 
were quantified as photons per second per square centimeter per steradian (ps–1per cm2 per 
sr1). Progression and spread of tumors were evaluated by calculating the tumor radiance 
values from inoculated mice in each group. Tumor-bearing mice were used in experiments 
approximately 14 days following implantation or 21 days in the metastases model when the 
pulmonary tumors develop following orthotopic implantation of the tumor cells into the 
prostate17. Mice not developing tumors were excluded from the experiments (<5%). All 
mice were closely monitored and any displaying signs of rapid weight loss, excessively 
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large tumours (>1010 ps-1, or 15 mm in diameter) or any pain/suffering/distress sufficient to 
impede natural behavior were culled.
Use of the MRI scanner to direct cell movement
Three million MDMs with or without SPIOs were administered via tail vein in 100μl 
volume of PBS (n=5), control groups received 100ul PBS (n=5), or 100ul PBS containing 3 
× 106 macrophages without SPIOs (n=5). Immediately after MDM administration mice were 
anaesthetized with gaseous isoflurane (Abbott, UK) and then secured within a magnet-
compatible holding capsule and MR targeting was carried out immediately using a 7 Tesla 
small bore magnet with a 660mT/m gradient insert (Bruker BGA 12-S).
Mice were split into 2 groups of n=5. Group 1 was a time-matched control without MR 
targeting and Group 2 underwent 1 hour of MR targeting with gradients pulsed 2ms on, 7ms 
off at 50% total strength (300mT/m); and applied direction selected for coarse steering to the 
tumor site for the Prostate (−z, −y) (Fig. 2a). For steering to the lungs (+z and −y gradients), 
the absence of an × gradient should ensure even distribution of magnetic particles in each 
lung.
The force on magnetically labeled cells is dependent on whether the SPIOs have become 
magnetically saturated. When unsaturated, the force is dependent on the magnetic 
susceptibility of the SPIOs, the magnetic field and also the magnetic field gradient32. 
However once the SPIOs reach saturation, the force is no longer dependent on the magnetic 
susceptibility of the particle but the saturation magnetization and as such only the magnetic 
field gradient will affect the force applied to the cells7. SPIOs typically reach magnetic 
saturation well below 1T, for example in Riegler et al6, where the SPIOs become saturated 
at around 300mT, therefore MRT is feasible on clinical MRI systems provided the same 
magnetic field gradient is used ~300mT/m.
Following MRI-steering, high-resolution RARE (TR = 4.2s, TE=12ms, RARE factor 8, 
512*192, no averaging, 9 slices 1mm thick) and gated FLASH (TR = 8.9ms, TE = 1.2ms, 24 
reps, 128*128, FA 15°) images of the tumor (prostate only) were captured using a 1H 
volume resonator (Bruker, 300MHz, 1kW max, outer diameter 118mm/ inner diameter 
72mm). Once complete relaxometry-using MSME (TE 10ms, Echo Spacing 10ms, 16 
echoes, TR 2s, matrix size 256*256) and MGE (TE 2.5ms, Echo Spacing 3.7ms, 12 echoes, 
TR 10s, matrix size 128*128, FA 90°) was performed to assess the transverse relaxation 
rates. After treatment, animals were sacrificed and tissues including tumors, kidney, liver, 
lungs and spleen, were either paraffin wax embedded and fixed for immunohistochemistry 
or analyzed by flow cytometry to determine macrophage uptake (see supplementary files for 
details).
Vascular permeability
A further study was performed to assess vascular permeability in mice. Mice were 
administered with 3 million SPIO-loaded MDM one group underwent MR targeting and the 
other remained in the scanner as described above. Immediately after targeting mice were 
injected i.v. with a 100 ul mixture of FITC-conjugated Lycopersicon esculentum (tomato) 
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lectin (1 mg/ml; Vector Laboratories) and Ricinus communis agglutinin I (2.5 mg/ml; Vector 
Laboratories). Perfusion-fixation with 4% paraformaldehyde was performed 10 min 
following lectin administration. Harvested tissue was post-fixed in 4% paraformaldehyde, 
processed through graded sucrose, and embedded in OCT medium (Tissue-Tek). Sections at 
approximately 40 um were counterstained with DAPI (0.05 mg/ml, Invitrogen) and confocal 
image stacks were acquired by confocal microscopy (Nikon). Measurement of vascular 
volumes was performed on images from tumor-bearing mice with and without MRT 
targeting (n=3 mice/group and 5-10 fields of view).
In addition vasculature leakage was also assessed using the contrast agent gadolinium-
diethylenetriaminepentaacetic acid (Gd-DPTA)31,32. Mice receiving SPIO-loaded MDM 
with and without MR targeting were removed from the scanner and injected (via tail vein) 
with a 0.1mmol/Kg dose of Gd-DPTA (Magnevist) (N=3 mice/group). Mice were then 
returned to the scanner and T1 weighted imaging (TR=100ms, TE=3.7ms, FA = 30 degs, 
matrix size=256*256) was performed for 15 minutes (50 repetitions) post injection. Data 
were used to assess pooling of the contrast agent over time as an indicator of a leaky, 
damaged vasculature. Experiments were repeated with Gd-DPTA alone (no iron labeled 
macrophages or MRT). Uptake of Gd-DTPA was monitored in tumour tissue over the 15-
minute period; any pooling would result in increased signal over this time period. We also 
monitored GD-DTPA uptake in the muscle surrounding the spinal cord (vertically away 
from the −y gradient targeted tumour region) as a control region where we expect no 
vascular disruption due to MRT. Direct comparisons in changes in signal intensity were 
made between these two regions to investigate any vascular damage in the targeted region. 
Finally, if there is no vascular damage Gd-DTPA should enter the renal system; to confirm 
this in our groups we imaged the kidneys.
Therapeutic studies
HSV1716 in vitro studies are described in the accompanying supplementary file. In vivo 
studies were performed as follows. Tumor bearing mice received tail vein injections of 
either 3 million MDM alone or armed with Seprehvir at MOI 50, 1×107 Seprehvir only or 
PBS (n=5 mice/group). Of note, 3 groups of mice were administered MDM +OV, one group 
underwent MR targeting for 1h, one sat in the MRI scanner but had no MR targeting (MDM
+OV no MRT) and another group did not enter the MRI scanner (MDM+OV). Tumor size 
was monitored by IVIS Lumina II imaging (IVIS, Caliper Life Sciences). Animals were 
sacrificed once tumors reached the maximum volume (>1010 ps-1) permitted by UK Home 
Office Regulations. Excised tissues including tumors, kidney, liver, lungs, and spleen were 
embedded in OCT or paraffin wax for immunocytochemical/ histologic labeling studies.
Histological analysis
Tissues were divided into two; one part was formalin fixed for immunohistological analysis 
and the other was dissected free of adherent fibrous and fatty tissue and treated with 
collagenase. Flow cytometry: cell viability was determined using LIVE/DEAD Fixable 
Violet Dead Cell Stain Kit (Invitrogen). All FACS data were analyzed on an LSR II flow 
cytometer (BD Biosciences) using FlowJo software (Tree Star). Histology: Five micron 
sections of all organs were incubated with specific antibodies for target antigens; for the 
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vasculature we used CD31 (1:100), (AbD Serotec) and for macrophages human CD68 
(Dako, Ely, UK) at 1:100. A biotinylated secondary antibody system was used in 
conjunction with a streptavidin-conjugated HRP. Peroxidase activity was localised with 
diaminobenzidine (Vectastain Elite ABC kit, Vector Labs). To detect iron in the tumors 
(where cell densitites were high) sections were stained with Perls Prussian blue and counter-
stained with eosin for improved contrast. To detect cancer cells in the lungs all lung sections 
were stained with Epithelial cell adhesion molecule (EPCAM) or Hematoxylin and eosin 
(H&E). All immune-localization experiments were repeated on multiple tissue sections and 
included isotype-matched controls for determination of background staining. To assess 
necrosis the area of necrosis within the whole-tumor section was determined visually, and 
the proportion of necrotic nonviable tumor areas over the whole section was calculated using 
ImageJ software (National Institute of Health). For each group, the mean percentage of 
necrosis and standard error were calculated. The results are presented as the mean tumor 
necrosis (%) for all tumors (five slices per each tumor) in each treatment group. 
Immunofluorescence: Harvested tissue was post-fixed in 4% paraformaldehyde, processed 
through graded sucrose, and embedded in OCT medium (Tissue-Tek) and stored at −80°C. 
Frozen sections were dried for 10 minutes at room temperature and blocked in 5% horse 
serum + 0.5% saponin in PBS for 30 minutes. Sections at approximately 4 μm were stained 
with anti-GFP 1:200 (ab290 abc anti UK) and CD68 (1:100) for 1 hour and then secondary 
antibodies donkey anti-rabbit alexa fluor 488 and goat anti-mouse 540 at 1:100 dilution 
(Invitrogen, Paisley, UK) and finally counterstained with prolong gold-antifade mountant 
with DAPI (4′,6-diamidino-2-phenylindole 0.05 mg/ml, Invitrogen). Images of macrophage 
infiltration into primary and pulmonary LnCAP tumors were captured using a spinning disc 
confocal microscope (Olympus IX81, PerkinElmer, UK). Confocal image Z-stacks of 
tumors were captured at 1μm increments at ×20 magnification.
Statistical analysis
Data are means ± SEM (Prism 5; GraphPad Software). Two-tailed student’s t test were used 
to analyze the statistical significance of the data unless otherwise stated. Differences were 
termed significant with a P value of less than 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MRT using a novel trans-endothelial migration (TEM) flow assay
We have designed a flow chamber that can accommodate 3D tumor spheroids as well as a 
vascular endothelial layer. The flowing ‘magnetic cells’ will therefore need to cross the 
vascular barrier before entering a 3D tumor simulating the passage of cells across 
endothelial cells in a blood vessel wall (a: left panel). The TEM flow chamber is placed in 
the iso-centre of an MRI scanner with a spherical (6mm diameter) homogenous 7T magnetic 
field. We applied a pulsed gradient (50% of max) with strength of 300mT/m in the (−y) 
gradient direction. The resulting heterogeneous magnetic field (dB/dy field) can steer 
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magnetic particles towards the tumor spheroids for increased uptake (a: right panel). Cell 
viability following SPIO uptake was not compromised as assessed by flow cytometry for 
propidium iodide uptake (b). Uptake was confirmed by a distortion in the MRI image and a 
loss of signal compared to when no MRT was applied (c, upper panel). Corresponding 
fluorescent images of wholes spheroids infiltrated with macrophages carrying a reporter 
adenovirus (AdCMVGFP) are shown in (c, 2nd panel). Bars = 100μm. Flow cytometry of 
enzymatically dispersed spheroids revealed that the number of magnetic-cells infiltrating 
spheroids (% of all cells present in spheroids that were CD14+) was significantly increased 
when a gradient was applied (c, lower panels). All images and data (means ± SEM) are 
derived from 6 independent experiments. Comparisons between groups were performed 
using two-tailed unpaired Student’s t-test p = 0.0001, compared with No MRT group.
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Figure 2. Magnetic macrophages were steered into primary prostate tumors using MRT
(a) Schematic of targeted regions using imaging gradients for MR Targeting. We applied a 
−Y gradient applied equally across the animal to target the location of the prostate as 
depicted (red box). Three million magnetically labelled macrophages were then 
administered to mice via i.v. injection and anesthetised mice were then placed into the 
isocentre of a 7T MRI scanner. Subjects were split into 2 groups with n=5 mice/group. 
Group 1 were imaged after 1 hour (no MR Targeting). Group 2 underwent MRI targeting. 
Post mortem we confirmed the increased levels of human macrophage uptake by (b) FACS 
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analysis of collagenase-treated tumors one hour after MRI targeting, and (c) histological 
staining of paraffin wax-embedded tumor sections with an anti-human CD68 antibody and 
Prussian blue (CD68 positive macrophages are brown and SPIO positive macrophages are 
blue: see arrows). Representative RARE images from 5 mice/group and R2 maps for each 
group are shown (d) and (e). T=Tumor, bars= 200μm. (f) The number of perfused vessels in 
tumors in mice who underwent MRT compared to mice with no MRT was determined by 
perfusion with tomato lectin (green). Arrows point to areas vascular leakage. Mean ± SEM, 
p=0.75, Student’s t test; analysis of tumors from n=5 mice per group and 5–10 fields of view 
(FOV) per tumor. The total volume of leaky vasculature does not differ between tumors in 
the two groups of mice (mean ± SEM; p=0.6, Student’s t test; analysis of tumors from 3 
mice per group and 5–10 FOV per tumor). Bar= 34μm.
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Figure 3. MR targeting of magnetic cells into tumors does not affect vasculature
Representative maps of Gadolinium pooling are shown for each group of mice where n=3 
mice/group. The position of the slices (yellow) from which the MRI images were taken is 
shown - one for the kidneys and the other the tumour (a). In all cases the T1 weighted 
images show higher signal intensity in the kidneys (b; upper panel) than in the prostate 
tumors (b; lower panel), where gadolinium pooled within the urinary system of the mice 
following administration. (c) Regions of interest were taken in kidney, tumour and muscle 
tissue and time series analysis of contrast agent pooling is shown for the MRT group and 
time matched ‘no MRT’ group. Both muscle and tumour tissue show no apparent change in 
MR signal intensity over time compared to the kidney, providing further evidence that the 
vasculature has remained intact following MRT therapy. All data are means ± SEM from 
n=3 mice/group.
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Figure 4. Magnetic macrophages were steered into pulmonary metastasis using MRT
Short-pulsed magnetic gradients were used to steer SPIO-loaded macrophages towards the 
lungs. (a) FACS analysis of collagenase-treated lungs showed significantly more human 
CD14+ macrophages were present in lungs with than without MR targeting. Analysis of 
tumors from n=3 mice per group where data are mean ± SEM, student’s t test *, P < 0.01 
compared with non-MR targeted lungs. (b) Representative images from n=3 mice/group are 
shown, this revealed increased immunostaining for human CD68 and Prussian blue in lung 
sections (CD68+ cells are brown and SPIO+ cells blue: see arrows). Bar = 75μm. This was 
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also confirmed in immunofluorescence stained sections using an anti-GFP antibody/green 
and CD68/red (bar = 75μm, M=metastasis and arrows point to CD68+ve cells) (c) 
Immunostaining with CD31 (Bar= 50μm) and H&E (Bar=200μm) indicated that MR 
targeted delivery of magnetic macrophages into the lungs had no adverse affects on the lung 
vasculature compared to delivery without targeting. Representative data are shown from one 
of two replicate experiments in which n=3 mice/group. SEMs are depicted and student t-test 
P < 0.75 compared MR targeted with non-MR targeted lungs.
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Figure 5. Magnetic targeting increases the anti-tumor effects of oncolytic macrophage
Tumor-bearing mice were administered with a single dose of human monocyte-derived 
macrophages (MDM) carrying the oncolytic virus, HSV1716 (MDM+OV). These were 
divided into three groups of mice (each with 5 mice/group). One group underwent MR 
targeting to either the prostate gland or lungs (MDM+OV+MRT) for 1 h, another was 
exposed to the MRI scanner but with no MR targeting (MDM+OV no MRT) and the third 
(MDM+OV) did not enter the MRI scanner. Additional groups of mice received 100ul of 
PBS (Control), a single dose of 1 × 107 pfu HSV1716 (OV) or 3 million untreated MDM. 
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Mice were imaged weekly using the IVIS imaging system and, after 21 days, tumors and 
lungs were removed and processed for histology. (a) Tumor luminosity in n=5 mice/group 
showed MR Targeting significantly improved the effect of OV-MDM on tumor growth (b) 
Representative IVIS images and photographs of primary tumors following various 
treatments (c) Representative RARE images for MDM+OV with or without MR targeting 
show marked difference in tumor size at the beginning and end of therapy. Representative 
images of H&E stained sections from n=5 mice/group show (d) the area of necrosis (N) in 
primary tumors and (e) the number of metastases (see arrow, M=Metastasis) in the lungs of 
mice receiving MDM+OV with or without MR targeting Bars in panels d-e= 200 μm. Data 
shown are means ± SEMs of n=5 mice/group. For the lung metastasis quantitative analysis 
was carried out on 10 high-power fields (HPF; ×20 magnification) per tissue section. 
Comparisons between more than two groups were performed using one-way ANOVA 
followed by post-hoc Bonferroni test. *P < 0.05; **P < 0.001; ***P < 0.0001 compared with 
MDM+OV+MRT to MDM+OV (no MR targeting) and ^ is comparing MDM+OV (no MR 
targeting) and free OV group.
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Figure 6. Principle of MR targeting to steer cell-based therapies to specific tissues
(a) The cells used for these studies are derived from monocytes isolated from patient blood. 
These cells are cultured in the presence of various stimuli to produce ‘therapeutic’ 
macrophages (e.g. cytokines, therapeutic genes or viruses) and loaded with SPIOs before re-
infusion back into the same patient. (b) The subject is then placed in the centre of an MRI 
scanner where linear spatial encoding magnetic gradients can be used to induce a force on a 
magnetized body. The magnetic cells injected into the bloodstream of the subject circulate 
and are targeted into the diseased organ/tissue under the influence of the applied magnetic 
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field. Field map plots demonstrate that significant field gradients can be generated in various 
directions by the MRI gradient coils. The resulting magnetic field (dB/dy field) can steer 
magnetic cells towards the diseased tissue for increased cell uptake.
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